RE: Analysis15 Jan 2025 08:49
@GG you can’t ever call a bottom, but be comfortable in your purchase. I bought some of these at 18p and also 7p, so I know with a late stage Lupus product and investment from Avion since 2019 totalling some 35M our 13m market cap is more than attractive. The peptide and autoimmune research is a big bonus and their use case can transform the business. Now I don’t know how true the comments yesterday are about a link up with Moderna is, however there is an IMMUPHARMA subsidiary in France, so this plausible. Having double checked Moderna are at attending the BioTech Conference,l along with a slew of big hitters - time will tell what Tim and the team have managed to negotiate.